Bayer Healthcare and Comgenex Extend Drug Discovery Collaboration
Bayer Healthcare and ComGenex announced that they have renewed their exclusive chemistry collaboration for the sixth consecutive year.
"As a result of ComGenex high scientific and quality standards we are glad to continue the collaboration for the coming year. During the past several years ComGenex has built a knowledge base that has great value for Bayer and that we could efficiently utilize in our drug discovery process. The flexibility and expertise of ComGenex in responding to Bayer's high standards shows that ComGenex is a reliable high-quality partner," said Dr. Hanno Wild, Head of Medicinal Chemistry at Bayer HealthCare.
During the extended term ComGenex will focus on further improving the overall properties of compound libraries by applying proprietary design criteria and extending chemical diversity. The provided potentially bioactive compound libraries will be used for applications in all discovery research areas of Bayer HealthCare's pharma division.
"The extension of our collaboration and arrangements shows that the ComGenex chemistry team is committed to satisfy the ever increasing demands of our partners. Our hard work over the years has paid off and we are glad that we were able to build a knowledge base and service portfolio that leading pharmaceutical companies like Bayer can utilize efficiently in their discovery process," said Dr. László Ürge, CEO of ComGenex.
Other news from the department science
![[Fe]-hydrogenase catalysis visualized using para-hydrogen-enhanced nuclear magnetic resonance spectroscopy](https://img.chemie.de/Portal/News/675fd46b9b54f_sBuG8s4sS.png?tr=w-712,h-534,cm-extract,x-0,y-16:n-xl)
